Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + lazertinib + bevacizumab in EGFR-mutant advanced non-small cell lung cancer after progression on third-generation EGFR TKI
2021-002337-42Phase 2Active
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab, lazertinib, bevacizumab and osimertinib in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Objective response rate. Started Nov 2022; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-002337-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002337-42.